image credit: Unsplash

Cancer Immunotherapy Study Identifies New Checkpoint Targets in Myeloid Cells

Many cancer patients derive little benefit from checkpoint inhibitors, drugs that target immune system checkpoints, mechanisms that temper immune responses. To date, most checkpoint inhibitors target checkpoints on T cells to unleash T cells’ full anticancer potential. But new checkpoint inhibitors could target cells of a different kind, myeloid cells, potentially enhancing cancer immunotherapy. Specifically, checkpoint inhibitors could target c-Rel, a protein expressed by myeloid cells, to block the generation of myeloid-derived suppressor cells (MDSCs).

Read More on Genetic Engineering and Biotechnology News